DD281807A5 - Verfahren zur trennung der d- und l-enantiomeren von medetomidin - Google Patents
Verfahren zur trennung der d- und l-enantiomeren von medetomidin Download PDFInfo
- Publication number
- DD281807A5 DD281807A5 DD88317936A DD31793688A DD281807A5 DD 281807 A5 DD281807 A5 DD 281807A5 DD 88317936 A DD88317936 A DD 88317936A DD 31793688 A DD31793688 A DD 31793688A DD 281807 A5 DD281807 A5 DD 281807A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- medetomidine
- enantiomers
- alpha
- optically active
- enantiomer
- Prior art date
Links
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 229960002140 medetomidine Drugs 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 239000000018 receptor agonist Substances 0.000 claims abstract description 4
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 4
- 239000000730 antalgic agent Substances 0.000 claims abstract description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims abstract description 3
- 239000002220 antihypertensive agent Substances 0.000 claims abstract description 3
- 238000001640 fractional crystallisation Methods 0.000 claims abstract description 3
- 239000011833 salt mixture Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000003389 potentiating effect Effects 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000001624 sedative effect Effects 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 abstract description 6
- 239000002249 anxiolytic agent Substances 0.000 abstract description 4
- 229940126601 medicinal product Drugs 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 229960002896 clonidine Drugs 0.000 description 9
- 239000000556 agonist Substances 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 108060003345 Adrenergic Receptor Proteins 0.000 description 4
- 102000017910 Adrenergic receptor Human genes 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008484 agonism Effects 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 3
- 229960001894 detomidine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960001289 prazosin Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- -1 salycilates Chemical class 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001177 vas deferen Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- PYLVMOIJXGAQHY-UHFFFAOYSA-N C12(C(=O)CC(CC1)C2(C)C)CS(=O)(=O)O.C(C(O)C(O)C(=O)O)(=O)O Chemical compound C12(C(=O)CC(CC1)C2(C)C)CS(=O)(=O)O.C(C(O)C(O)C(=O)O)(=O)O PYLVMOIJXGAQHY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000000059 bradycardiac effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Optical Record Carriers And Manufacture Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Photoreceptors In Electrophotography (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8716803A GB2206880B (en) | 1987-07-16 | 1987-07-16 | Optical isomers of an imidazole derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD281807A5 true DD281807A5 (de) | 1990-08-22 |
Family
ID=10620775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD88317936A DD281807A5 (de) | 1987-07-16 | 1988-07-14 | Verfahren zur trennung der d- und l-enantiomeren von medetomidin |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US4910214A (da) |
| EP (1) | EP0300652B1 (da) |
| JP (1) | JPH0625138B2 (da) |
| KR (1) | KR940007311B1 (da) |
| CN (1) | CN1022323C (da) |
| AT (1) | ATE71941T1 (da) |
| AU (1) | AU600839B2 (da) |
| BG (1) | BG60473B2 (da) |
| CA (1) | CA1337659C (da) |
| CY (2) | CY1787A (da) |
| DD (1) | DD281807A5 (da) |
| DE (2) | DE10399005I2 (da) |
| DK (1) | DK165788C (da) |
| ES (1) | ES2038757T3 (da) |
| FI (1) | FI95375C (da) |
| GB (1) | GB2206880B (da) |
| GR (1) | GR3003878T3 (da) |
| HK (1) | HK56094A (da) |
| HU (1) | HU198693B (da) |
| IE (1) | IE60456B1 (da) |
| IL (1) | IL87076A0 (da) |
| LU (1) | LU91010I2 (da) |
| NL (1) | NL300117I2 (da) |
| NO (2) | NO170579C (da) |
| NZ (1) | NZ225362A (da) |
| PT (1) | PT88013B (da) |
| SU (1) | SU1648248A3 (da) |
| UA (1) | UA5560A1 (da) |
| ZA (1) | ZA885134B (da) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| US5124157A (en) | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| US5120713A (en) * | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
| GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
| GB2281206A (en) * | 1993-08-25 | 1995-03-01 | Orion Yhtymae Oy | Use of dexmedetomidine |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| IN187238B (da) * | 1995-06-30 | 2002-03-09 | Astra Ab | |
| GB9521680D0 (en) * | 1995-10-23 | 1996-01-03 | Orion Yhtymo Oy | New use of imidazole derivatives |
| US5866579A (en) * | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
| AR015744A1 (es) * | 1998-04-01 | 2001-05-16 | Orion Corp | Uso de dexmedetomidina para sedacion en terapia intensiva |
| US6716867B1 (en) | 1998-04-01 | 2004-04-06 | Orion Corporation | Use of dexmedetomidine for ICU sedation |
| DE60024855T2 (de) | 1999-10-29 | 2006-08-31 | Orion Corp. | Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock |
| US6388090B2 (en) * | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
| US7141597B2 (en) * | 2003-09-12 | 2006-11-28 | Allergan, Inc. | Nonsedating α-2 agonists |
| KR20080065704A (ko) | 2005-11-09 | 2008-07-14 | 콤비네이토릭스, 인코포레이티드 | 의학적 이상의 치료 방법들, 조성물들, 및 키트들 |
| WO2007109104A2 (en) | 2006-03-16 | 2007-09-27 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
| US7795263B2 (en) * | 2008-07-08 | 2010-09-14 | Wildlife Laboratories, Inc. | Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals |
| US20100196286A1 (en) * | 2008-12-01 | 2010-08-05 | Armer Thomas A | Inhalation delivery methods and devices |
| WO2010074753A1 (en) | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
| WO2010132882A2 (en) * | 2009-05-15 | 2010-11-18 | Recro Pharma, Inc. | Sublingual dexmedetomidine compositions and methods of use thereof |
| CN101671305A (zh) * | 2009-09-29 | 2010-03-17 | 北京华禧联合科技发展有限公司 | 一种拆分美托咪定的左旋及右旋对映体的方法 |
| CN102464619A (zh) * | 2010-11-17 | 2012-05-23 | 桑迪亚医药技术（上海）有限责任公司 | 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法 |
| US20130096170A1 (en) | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
| WO2013069025A1 (en) | 2011-11-11 | 2013-05-16 | Neon Laboratories Ltd. | "process for the preparation of dexmedetomidine" |
| BR112014019171A8 (pt) | 2011-12-11 | 2017-07-11 | Recro Pharma Inc | Composições intranasais de dexdetomida e seus métodos de uso |
| US8242158B1 (en) | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
| ITMI20120311A1 (it) * | 2012-02-29 | 2013-08-30 | Edmond Pharma Srl | Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| HUE037272T2 (hu) | 2012-10-15 | 2018-08-28 | Orion Corp | Állatorvosi módszer zajérzékenység enyhítésére |
| JP6188933B2 (ja) | 2013-10-07 | 2017-08-30 | テイコク ファーマ ユーエスエー インコーポレーテッド | 非鎮静量のデクスメデトミジンの経皮送達用方法及び組成物 |
| TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
| CN106456561B (zh) | 2013-10-07 | 2020-02-28 | 帝国制药美国公司 | 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物 |
| CN105175339B (zh) * | 2015-10-09 | 2018-01-16 | 辰欣药业股份有限公司 | 一种制备盐酸右美托咪定的方法 |
| US9717796B1 (en) | 2016-04-20 | 2017-08-01 | Slypharma, Llc | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
| FR3054218B1 (fr) * | 2016-07-22 | 2020-03-06 | Universite De Rouen | Procede de dedoublement de sels de baclofene |
| US11160791B2 (en) | 2018-11-01 | 2021-11-02 | Medefil, Inc. | Dexmedetomidine injection premix formulation in ready to use (RTU) bags |
| CN114671811A (zh) * | 2022-04-14 | 2022-06-28 | 南京正科医药股份有限公司 | 一种右美托咪定拆分副产物的外消旋化回收方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| GB2092569B (en) * | 1981-02-05 | 1984-09-19 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| FI844786A0 (fi) | 1984-12-04 | 1984-12-04 | Farmos Oy | Terapeutiskt utnyttjbar foerening. |
| DE3531682A1 (de) * | 1985-09-05 | 1987-03-12 | Thomae Gmbh Dr K | (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel |
-
1987
- 1987-07-16 GB GB8716803A patent/GB2206880B/en not_active Expired - Lifetime
-
1988
- 1988-06-14 FI FI882819A patent/FI95375C/fi active Protection Beyond IP Right Term
- 1988-06-28 SU SU884356076A patent/SU1648248A3/ru active
- 1988-06-28 UA UA4356076A patent/UA5560A1/uk unknown
- 1988-07-08 ES ES198888306250T patent/ES2038757T3/es not_active Expired - Lifetime
- 1988-07-08 EP EP88306250A patent/EP0300652B1/en not_active Expired - Lifetime
- 1988-07-08 DE DE2003199005 patent/DE10399005I2/de active Active
- 1988-07-08 DE DE8888306250T patent/DE3867945D1/de not_active Expired - Lifetime
- 1988-07-08 AT AT88306250T patent/ATE71941T1/de active
- 1988-07-11 NZ NZ225362A patent/NZ225362A/xx unknown
- 1988-07-11 AU AU18941/88A patent/AU600839B2/en not_active Expired
- 1988-07-11 DK DK386288A patent/DK165788C/da not_active IP Right Cessation
- 1988-07-12 IL IL87076A patent/IL87076A0/xx not_active IP Right Cessation
- 1988-07-14 CA CA000572086A patent/CA1337659C/en not_active Expired - Lifetime
- 1988-07-14 DD DD88317936A patent/DD281807A5/de not_active IP Right Cessation
- 1988-07-15 ZA ZA885134A patent/ZA885134B/xx unknown
- 1988-07-15 NO NO883155A patent/NO170579C/no not_active IP Right Cessation
- 1988-07-15 KR KR1019880008937A patent/KR940007311B1/ko not_active IP Right Cessation
- 1988-07-15 PT PT88013A patent/PT88013B/pt not_active IP Right Cessation
- 1988-07-15 US US07/219,637 patent/US4910214A/en not_active Expired - Lifetime
- 1988-07-15 HU HU883708A patent/HU198693B/hu unknown
- 1988-07-15 IE IE217488A patent/IE60456B1/en not_active IP Right Cessation
- 1988-07-16 JP JP63177959A patent/JPH0625138B2/ja not_active Expired - Lifetime
- 1988-07-16 CN CN88104440A patent/CN1022323C/zh not_active Expired - Lifetime
-
1992
- 1992-02-21 GR GR920400299T patent/GR3003878T3/el unknown
-
1994
- 1994-01-18 BG BG098380A patent/BG60473B2/bg unknown
- 1994-05-24 HK HK56094A patent/HK56094A/xx not_active IP Right Cessation
-
1995
- 1995-10-20 CY CY178795A patent/CY1787A/xx unknown
-
2003
- 2003-02-14 LU LU91010C patent/LU91010I2/fr unknown
- 2003-03-03 NL NL300117C patent/NL300117I2/nl unknown
- 2003-07-01 NO NO2003004C patent/NO2003004I2/no unknown
-
2004
- 2004-10-27 CY CY200400006C patent/CY2004006I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD281807A5 (de) | Verfahren zur trennung der d- und l-enantiomeren von medetomidin | |
| DE69031290T2 (de) | Verwendung von Sertindol zur Behandlung von Schizophrenie | |
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DD201139A5 (de) | Verfahren zur herstellung von (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamin und seinen pharmazeutisch unbedenklichen salzen | |
| DE69928806T2 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| DE3785549T2 (de) | Anxiolytisches praeparat. | |
| DE69131398T2 (de) | Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall | |
| EP0312913B2 (de) | Verwendung von paf-Acether-Antagonisten zur Herstellung eines Arzneimittels und Verfahren zu deren Wirksamkeitsbestimmung | |
| DE2920254A1 (de) | Pharmazeutische dosierungskomponente mit gesteuerter freisetzung und verfahren zu deren herstellung | |
| DE2635961A1 (de) | Therapeutisch wirksame verbindungen und verfahren zu ihrer herstellung | |
| DE2403122C2 (da) | ||
| WO1992019245A1 (de) | Verwendung von torasemid zur behandlung von hirnödemen | |
| DE2300614A1 (de) | Neue optisch aktive verbindungen | |
| DE2658500C2 (de) | Pharmazeutische Präparate mit kardioprotektiver Wirkung | |
| DE2034640C3 (de) | l-p-(7-Trifluormethyl-4-chinolyl) -amino-benzoyl-piperazine, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Bluthochdruck | |
| DE2823268C2 (da) | ||
| DE69814669T2 (de) | Pharmaceutische Zusammensetzung enthaltend (+)-EPHEDRIN und einen H1 Rezeptor Antagonisten | |
| EP0192098B1 (de) | Verwendung des 2-Amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepins zur Herstellung eines zur Behandlung der Parkinsonschen Erkrankung bzw. des Parkinsonismus geeigneten Arzneimittels | |
| DE2720194A1 (de) | Verwendung von trazodon und etoperidon zum behandeln des parkinson-tremors und anderer extra- pyramidaler syndrome | |
| DE69701139T2 (de) | Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität | |
| DE2749075C2 (da) | ||
| DE2855306A1 (de) | Mittel zur senkung der herzfrequenz | |
| DE2810051A1 (de) | Zubereitung fuer die behandlung von asthma | |
| EP0417637A2 (de) | Verwendung von Dopamin-Autorezeptor-Agonisten bei der Behandlung von Drogenabhängigkeit | |
| DE2212600C3 (de) | d- und l-1-(4-Amino-3,5-dichlorphenyl)-2-alkylamino-äthanole und deren Säureadditionssalze, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |